Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HEB = STRONG BUY for Monday June 8, 2009
Written by jinandjuice2009
June 6, 2009 at 3:37 PM
http://jinandjuice2009.wordpress.com/2009/06/06/heb-strong-buy/
*** LONG-portfolio 0815ax (BigBoards) 06/2009 ***
ACAS - CENX - CTIC * - CPE - GNW - HIG - KV.A
MTG * - NEXM - PLD * - STP - SRZ - XL - XTXI * - YGE
* ~ "free shares"
*** LONG-portfolio 0815ax (OTCBB) 06/2009 ***
JGBO - NEOM
*** (Q)-portfolio 0815ax (Chapter11) 06/2009 ***
CEMJQ - LEHMQ - SSCCQ - WAMUQ
DPDW _bbb_ comment:
This was just posted on DPDW board, i still like what i see, disregarding of what the naysayers post all day.
DPDW just needs time IMO !!
Great post by spec machine:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38470308
_bbb_
AZN, BMY Present Data on Experimental Diabetes Drug
Written by Staff and Wire Reports
Saturday, 06 June 2009 14:06
http://biomedreports.com/articles/latest-news/1170-azn-bmy-present-data-on-experimental-diabetes-drug.html
XOMA Presents Phase 1 Diabetes Trial Data
Written by Staff and Wire Reports
Saturday, 06 June 2009 14:16
http://biomedreports.com/articles/latest-news/1171-xoma-presents-phase-1-diabetes-trial-data.html
Generex to Present Positive Study Data At American Diabetes Association Scientific Sessions 2009
On Thursday June 4, 2009, 9:30 am EDT
http://finance.yahoo.com/news/Generex-to-Present-Positive-pz-15437855.html?.v=1
FDA, Clinical Trial Updates: ADLS, CLDA, GENZ, ISTA, Theratech
Posted by: Mike Havrilla in Untagged on Jun 02, 2009
http://biomedreports.com/blog/FDA-Clinical-Trial-Updates-CLDA-GENZ-ISTA-Theratech.html?blogger=Mike+Havrilla
Cell Therapeutics Says Brown Uty. Study Reveals High Pathological Complete Response Rate for OPAXIO Treatment in Esophagus Cancer - Update
6/3/2009 1:24 PM ET
http://www.rttnews.com/ArticleView.aspx?Id=968824
DVAX News !
Dynavax Presents Additional Phase 3 Data for HEPLISAVTM Hepatitis B Vaccine at DDW Medical Conference
HEPLISAV Demonstrates Rapid, Increased Protection for Adults
http://finance.yahoo.com/news/Dynavax-Presents-Additional-bw-15423889.html?.v=1
_bbb_
SNSS - Sunesis Pharmaceuticals (DD)
http://www.sunesis-pharma.com/
Corporate Presentation (April2009)
http://ir.sunesis.com/common/download/download.cfm?companyid=SUNP&fileid=263530&filekey=543BAAE7-D924-40BE-92E1-99C2A4F71544&filename=Corporate_Presentation.pdf
Voreloxin
Advanced Hematologic and Solid Tumor Malignancies
http://www.sunesis-pharma.com/products-in-development/products-in-development/product/Voreloxin.php
SNS-314
Potent and Selective Inhibitor of Aurora Kinases A, B, and C for Advanced Solid Tumors
http://www.sunesis-pharma.com/products-in-development/product/314.php
http://www.finviz.com/quote.ashx?t=snss&ta=1&p=d
CTIC News !
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
* On Tuesday June 2, 2009, 1:30 am EDT
http://finance.yahoo.com/news/Pixantrone-Produces-High-prnews-15407916.html?.v=2
13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update
Posted by: Mike Havrilla in Untagged on Jun 01, 2009
http://biomedreports.com/blog/13-Extreme-FDA-Trades-BioMedReports.com-6-1-09-Update.html?blogger=Mike+Havrilla
COIN News !
Converted Organics Ships Record Amount of Organic Fertilizer from Gonzales, Calif., Manufacturing Facility
Date : 06/02/2009 @ 9:15AM
http://ih.advfn.com/p.php?pid=nmona&cb=1243951948&article=38018209&symbol=N^COIN
0815ax
RZ News !
Raser Announces Filing of Universal Shelf Registration
Date : 06/01/2009 @ 5:00PM
http://ih.advfn.com/p.php?pid=nmona&cb=1243951948&article=38006436&symbol=NY^RZ
0815ax
CRGN News !
CuraGen Updates CR011-vcMMAE Data at ASCO
Date : 06/02/2009 @ 6:30AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1243941061&article=38012746&symbol=N%5ECRGN
_bbb_
IBOX updated & ...
_bbb_ in jail (again)
... we have a winner on PLI-board!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35108119
CTIC Jan. 27: Close $0.11
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
* On Monday June 1, 2009, 2:00 pm EDT
http://finance.yahoo.com/news/Pixantrone-Significantly-prnews-15401853.html?.v=1
1:45PM Cell Therapeutics trading halted - news pending (CTIC)
http://finance.yahoo.com/marketupdate/inplay#ctic
Generex Presents Positive Results of Phase 1 Prostate Cancer Vaccine Trial At the American Society of Clinical Oncology
WORCESTER, Mass., June 1, 2009
http://www.globenewswire.com/newsroom/news.html?d=166393
SNSS - Conference Call Information
http://finance.yahoo.com/news/Sunesis-Announces-New-Data-on-prnews-15343885.html?.v=2
Sunesis management, joined by voreloxin clinical investigators, will host a conference call to discuss the voreloxin clinical data presented at the ASCO 2009 Annual Meeting on Monday June 1, 2009, at 1:00 p.m. ET / 10:00 a.m. PT. Individual and institutional investors can access the call via 1-877-856-1961 (U.S. and Canada) or +1-719-325-4787 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website until June 15, 2009.
Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting
* On Monday June 1, 2009, 9:00 am EDT
http://finance.yahoo.com/news/Sunesis-Pharmaceuticals-prnews-15397806.html?.v=1
Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting
* On Monday June 1, 2009, 9:00 am EDT
http://finance.yahoo.com/news/Sunesis-Pharmaceuticals-prnews-15397806.html?.v=1
KERX is hotter !
May 29, 2009 Market Close: $ 0.70
pre-market 6:19 ($1.71)
...we need a name change too
like:
_bbb_ & friends - Longterm Investments, Biotechs & and Quapter11
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38274312
So this is now the "SSoS&S DD" board ..hehehe nice name change $heff great work as always..keep going on, i like it much !
btw
S&P500.png doesn't work!
have an other one??
axel
Stockwolf.com Selects KERX as Possible 5-bagger
Ethan Hastings
Monday, June 1, 2009
http://www.stockwolf.com/story/large-opportunity-small-cap-stocks
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
* On Friday May 29, 2009, 4:30 pm EDT
http://finance.yahoo.com/news/Keryx-Biopharmaceuticals-prnews-15389381.html?.v=2
KERK 29.05.2009 16:00 $0.70
KERX 29.05.2009 19:59 $1.01 ( http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=KERX&mkttype=after )
CTIC ... !
Full 2009 ASCO Cancer & Oncology Primer
Cell Therapeutics (NASDAQ: CTIC) is set to present its Pixantrone Phase III study results in June 1. At $1.23 its market cap is still listed around $560 million. That may have changed due to a tender, but its 52-week range is listed as $0.05 to $6.50. “Volatility is our middle name!”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38222764
Exelis-Sanofi Cancer Drug Deal
By Adam Feuerstein
6:15 a.m. EDT
http://www.thestreet.com/story/10506702/2/top-takes-from-real-money.html
Exelixis(EXEL Quote) licensed two early-stage cancer drugs to Sanofi-Aventis(SNY Quote) in a global partnership deal announced this morning that will pay Exelixis $140 million in upfront fees.
The two Exelixis cancer drugs involved in the deal are XL147 and XL765, both of which target the PI3K pathway in cells, which when activated, promotes cell survival and resistance to chemotherapy and radiation. Both drugs are currently in phase I studies.
Exelixis' CEO George Scangos had been promising more licensing deals for the many drugs in the company's pipeline, so I'd say he delivered well today.
If you're looking for possible ancillary trades off this EXEL-SNY deal, there a few other companies (none very well known) also developing PI3K pathway cancer drugs:
Keryx Biopharmaceuticals(KERX Quote) owns perifosine, which targets the AKT pathway, related to PI3K. The drug is in various phase I and phase II studies.
Rexahn Pharmaceuticals(RNN Quote), an Amex-listed stock with a drug, Archexin, in phase II.
Healthy Gains for Cancer Treatment Stocks
* On Thursday May 28, 2009, 12:28 pm EDT
http://finance.yahoo.com/news/Healthy-Gains-for-Cancer-indie-15371759.html?.v=1
The cancer therapy sector was up big on Thursday on deal making news and new potential for treatments.
The American Society of Clinical Oncology (ASCO), which begins Friday and lasts through Tuesday, is the biggest event of the year for cancer drug research, and it has put the spotlight on stocks in the sector. Today's news from Peregrine Pharmaceuticals (NASDAQ: PPHM - News) and Exelixis (NASDAQ: EXEL - News) is also stirring up interest among investors who are riding the stocks to massive gains.
The Cancer Stocks Index is composed primarily of biotech companies, whose drugs and devices are used in the treatment of cancer patients. It is up by 6.2% on the day, and it is beating the S&P 500 by 13.2% over the last month.
Peregrine Pharmaceuticals is leading the sector higher today, up by a whopping 65%. The company announced a new development in its Cotara clinical program. The drug, which has been tested on more than 115 patients with brain, colon, or liver cancer has shown potential as a treatment for a deadly form of brain cancer called glioblastoma (GBM). Company CEO Steven W. King said, "patients have tolerated the Cotara regimen well and we continue to see longer-term survivors among the treated patients." Investors are pushing the stock to a 52-week high above $1 on the news.
Separately, Elexis announced today that it will team up with Sanofi-Aventis (NYSE: SNY - News) on two of the company's cancer therapies. Investors like the news, sending Elexis shares up by 23%. Sanofi-Aventis, a pharmaceutical giant worth more than $80 billion, is up by 3%.
Other big winners in the cancer treatment industry are Aeterna Zentaris (NASDAQ: AEZS - News), Telik (NASDAQ: TELK - News), and Onyx Pharmaceuticals (Nasdaq: ONXX - News). All three are up by more than 4%.
Some micro-cap stocks are not participating in the rally today. Cell Genesys (NASDAQ: CEGE - News) and Keryx Biopharmaceuticals (NASDAQ: KERX - News) are both down more than -4.5%.
As of this writing, the Cancer Stocks Index is one of the top-30 performing tickerspy Indexes over the last month, with gains of 18.9%.
Investors can follow the Cancer Stocks Index and view related performance charts and metrics at tickerspy.com.
Developers Diversified Declares Second Quarter 2009 Common Share Dividend
Date : 05/28/2009 @ 4:17PM
http://ih.advfn.com/p.php?pid=nmona&cb=1243542147&article=37942833&symbol=NY^DDR
CLEVELAND, OH -- (Marketwire) -- 05/28/09 -- Developers Diversified Realty (NYSE: DDR), the nation's leading owner, manager and developer of market-dominant shopping centers, has declared its second quarter 2009 common stock dividend of $0.20 per share.
The common dividend is payable on July 21, 2009 to shareholders of record at the close of business on June 11, 2009.
In order to retain capital and enhance financial flexibility amid the challenging capital markets environment, and to comply with REIT distribution requirements, the Company has decided that the second quarter 2009 common stock dividend will be paid in a combination of cash and the Company's common shares. The cash component will not exceed 10% of the aggregate dividend, or $0.02 per share.
In accordance with recently issued Internal Revenue Service guidance, shareholders may make an election to receive their dividend in all cash or all common shares. However, to the extent more than 10% cash is elected by all shareholders in the aggregate, then the cash portion will be prorated.
Shareholders who do not make an election will receive 90% in common stock and 10% in cash. The value of the shares distributed in the dividend will be based upon the volume weighted average trading prices of the Company's common stock on July 7, July 8 and July 9, 2009.
The mailing of election forms to registered shareholders will commence no later than June 16, 2009, and must be received by the Company's transfer agent by 7:00 p.m. EDT on July 6, 2009.
Shareholders with questions may call Georgeson Inc. at 1-800-335-7830. If your shares are held through a bank, broker or nominee, and you have questions regarding the dividend election, please contact such bank, broker or nominee, who will also be responsible for distributing to you the election form and submitting the election form on your behalf.
Developers Diversified owns and manages over 700 retail operating and development properties in 45 states, plus Puerto Rico, Brazil, and Canada totaling approximately 153 million square feet. The Company is a self-administered and self-managed real estate investment trust (REIT) operating as a fully integrated real estate company which acquires, develops and leases shopping centers. Additional information about Developers Diversified is available on the Internet at www.ddr.com.
Contact:
Tom Morabito
Senior Director of Investor Relations
Developers Diversified Realty
Main: (216) 755-5500
E-mail: Email Contact
GNBT -
Generex Scientist to Participate in Panel Discussion At Swine Influenza Symposium
May 28, 2009 09:46
http://www.globenewswire.com/newsroom/news.html?d=166239
Generex Scientist to Participate in Panel Discussion At Swine Influenza Symposium
Symposium to be Hosted by The New York Academy of Sciences
WORCESTER, Mass., May 28, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that Dr. Douglas Powell, Director of Immunobiology at Antigen Express, Inc. (www.antigenexpress.com), Generex's wholly-owned immunotherapeutics subsidiary, will participate in a panel discussion this afternoon at the Human Swine Flu (H1N1) and Novel Influenza Pandemics symposium being hosted by The New York Academy of Sciences (NYAS) to be held at the NYAS conference center in New York City. The symposium will feature presentations by leaders in the field and will explore the latest swine influenza (H1N1 flu) outbreak with talks on the new reassortant virus, epidemiology, vaccines, treatment, and public health aspects.
Antigen Express is developing novel prophylactic vaccines for influenza. The Company has obtained broad and strong patent coverage for its proprietary platform technologies, which are designed to manufacture modified peptide vaccines by an entirely synthetic process, in contrast with egg-based or cell-culture-based vaccines that require expensive, extensive and labor-intensive manipulation. Antigen Express's entirely synthetic process reduces costs and increases both the speed and quantity of production. This is of particular benefit in meeting rapidly emerging viral threats such as the potentially pandemic H5N1 avian and H1N1 swine influenzas.
Mirion Technologies Releases New Compact Color Inspection and Surveillance Camera
Date : 05/27/2009 @ 1:00PM
Stock : Mirion Technologies (ACAS)
http://ih.advfn.com/p.php?pid=nmona&cb=1243518295&article=37916412&symbol=N^ACAS
Converted Organics & World Sports Alliance Name Control Power Systems Inc. Principal Contractor for Small Scale Waste-to-Fertilizer
Date : 05/28/2009 @ 9:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1243518295&article=37929646&symbol=N^COIN
Governor Arnold Schwarzenegger to Showcase Raser’s Electric Hummer H3 in a Demonstration Drive at the California State Capitol
Date : 05/28/2009 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1243518295&article=37926974&symbol=NY^RZ
Governor Arnold Schwarzenegger to Showcase Raser’s Electric Hummer H3 in a Demonstration Drive at the California State Capitol
Date : 05/28/2009 @ 8:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1243518295&article=37926974&symbol=NY^RZ
Raser Technologies, Inc. (NYSE: RZ), a leading energy technology company, will join with California Governor Arnold Schwarzenegger today to demonstrate Raser’s Electric Hummer H3, designed to achieve 100 mpg for a typical daily drive of 60 miles. The H3 uses an extended range electric vehicle (E-REV) powertrain developed by Raser Technologies. The Hummer H3 is a mid-sized SUV, similar in size to a Jeep Commander.
Governor Arnold Schwarzenegger will view the new plug-in electric Hummer H3 at the California State Capitol Thursday in a demonstration drive with Raser Chairman Kraig Higginson.
“I believe low-carbon fuel vehicles are the future and I want to see them succeed right here in California,” said Governor Schwarzenegger. “That’s why I’m bringing cars like this one to the Capitol where we can show the world there is a market for smart and innovative technologies that will also create jobs in the auto industry.”
According to a 2008 report by the U.S. Department of Transportation, trucks and SUVs account for nearly half the vehicles on the road and a majority of the emissions and fuel consumption.
“California has been known for its leadership in emissions and fuel economy standards which have been a driving force in establishing the new national CAFE standard,” said Kraig Higginson, Chairman of Raser Technologies. “We believe Raser’s E-REV powertrain will enable trucks and SUVs to meet or exceed this new standard while dramatically reducing emissions in larger vehicles,” added Higginson.
The most significant advantage of the E-REV is its ability to displace petroleum in favor of electric fuel, by driving the first 40 miles all on electricity. That’s significant because the majority of Americans drive fewer than 40 miles a day. “One of the best ways to improve gas fuel economy is not to burn gas,” stated David West, vice president of marketing for Raser Technologies and co-founder of the Plug-In Hybrid Development Consortium. “Most people will drive the Electric Hummer H3 primarily on electricity for about 60 cents per equivalent gallon of gasoline and will fill up with gas only a few times a year, rather than once a week,” added West.
In addition to plug-in electric vehicle technology, Raser is a leader in modular, low temperature geothermal power generation. Raser provides clean renewable geothermal power to California and intends to ramp up development of its large geothermal holdings to meet growing demand for base load renewable energy.
More information on the Electric Hummer H3 can be found at www.rasertech.com/hummer.